CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medite Cancer Diagnostics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medite Cancer Diagnostics Inc
414 N Orleans St Ste 502
Phone: (407) 849-0290p:407 849-0290 CHICAGO, IL  60654-4498  United States Ticker: MDITMDIT

Business Summary
MEDITE Cancer Diagnostics, Inc. (MEDITE) is a medical technology company specialized in the development, manufacturing, and marketing of premium medical devices, consumables and molecular biomarkers for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. The Company also develops, manufactures, markets, and sells MEDITE branded products (instruments and consumables), in the areas of histology and cytology. The Company has a distribution network to over 80 countries and a range of products for anatomic pathology, histology and cytology laboratories available for sale. The Company’s subsidiaries consist of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany and MEDITE Lab Solutions Inc.
(Source: 10-Q)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201812/31/2017YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board William A.Lewis 46 11/8/2017 2/12/2016
Chief Operating Officer MichaelaOtt 55 1/17/2018 4/3/2014
Chief Marketing and Business Development Officer JeffRencher 53 5/4/2017 5/4/2017
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
MEDITE GmbH Wollenweberstrasse 12 Burgdorf Germany

Business Names
Business Name
AccuMed International, Inc.
Bell National Corporation
CytoCore, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 5 (As of 3/27/2014)
Outstanding Shares: 86,723,700 (As of 11/10/2018)
Shareholders: 413
Stock Exchange: OTC
Federal Tax Id: 364296006
Fax Number: (312) 222-9580
Email Address: info@molecular-dx.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 29, 2023